风险投资视角下的创新药物研发激励体系模型研究  

Research on incentive system of innovative drug R&D from the perspective of venture capital

作　　者：武霞 邵蓉[1] WU Xia;SHAO Rong(National Drug Policy and Medical Industry Economy Research Center of China Pharmaceutical University,Nanjing 211198,China;China State Institute of Pharmaceutical Industry,Shanghai 201203,China)

机构地区：[1]中国药科大学国家药物政策与医药产业经济研究中心,南京211198 [2]中国医药工业研究总院,上海201203

出　　处：《中国新药杂志》2020年第20期2286-2293,共8页Chinese Journal of New Drugs

基　　金：国家社会科学基金重大项目:“我国创新药物政策环境研究”(15ZDB167)。

摘　　要：新药研发有高投入、高风险、高收益、周期长的突出特点,这与风险投资属性偏好一致。本文试图探讨如何激励创新药物风险投资中涉及的各方主体以吸引风险投资资金进入创新药物研发领域,通过对药物研发领域相关人员的访谈与问卷调研,从行为学、心理学角度,以结构方程构建以认知效能、预期效能、执行效能和反馈效能四大效能为一级指标的自我激励效能体系创新药物风险投资激励模型,为激励创新药物风险投资的相关工作者提供参考建议。New drug research and development is characterized by high investment, high risk, high yield and long cycle, which is consistent with the preference of venture capital. This paper attempts to explore how to encourage venture capital funds to enter the field of new drug research and development. The model is constructed by structural equation through the interview and questionnaire survey of pharmaceutical experts, from the perspective of behavioral science, psychology, which is based on the cognitive performance, expected effectiveness, executive function and performance feedback effectiveness for the primary index of self-motivation system for new drug venture capital incentive model. The model could provide some reference for those devoted to promoting the development of venture capital for drugs innovation.

关 键 词：创新药物研发 风险投资 激励体系模型 

分 类 号：R95[医药卫生—药学]